Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Katharina Kamm"'
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Cluster headache (CH) is associated with high disability. The Cluster Headache Impact Questionnaire (CHIQ) is a short, disease-specific disability questionnaire first developed and validated in German. Here, we validated the Engli
Externí odkaz:
https://doaj.org/article/62ca67da353e40188dc4b2c9d341edd2
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Cluster headache (CH) is a severe, highly disabling primary headache disorder. However, there is little research on CH-related disability, and most of it is based on non CH-specific questionnaires. The aim of this study was to dev
Externí odkaz:
https://doaj.org/article/ddb25b101e6d46ff9fcefa60c9b5f553
Autor:
Katharina Kamm
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
The multi-functional neuropeptide calcitonin gene-related peptide (CGRP) plays a major role in the pathophysiology of migraine. The detection of elevated CGRP levels during acute migraine headache was the first evidence of the importance of the pepti
Externí odkaz:
https://doaj.org/article/710deb268a0845a180dd3061eeb6733f
Autor:
Hans-Christoph Diener, Stefanie Förderreuther, Charly Gaul, Florian Giese, Till Hamann, Dagny Holle-Lee, Tim P. Jürgens, Katharina Kamm, Torsten Kraya, Christian Lampl, Arne May, Uwe Reuter, Armin Scheffler, Peer Tfelt-Hansen
Publikováno v:
Neurological Research and Practice, Vol 2, Iss 1, Pp 1-6 (2020)
Abstract Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (Erenumab) or against CGRP (Eptinezumab, Fremanezumab, Galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension o
Externí odkaz:
https://doaj.org/article/56f0e8b042604feab8e3f8dcf916a7d7
Autor:
Eloisa Rubio-Beltrán, Edvige Correnti, Marie Deen, Katharina Kamm, Tim Kelderman, Laura Papetti, Simone Vigneri, Antoinette MaassenVanDenBrink, Lars Edvinsson, On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-11 (2018)
Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks,
Externí odkaz:
https://doaj.org/article/cc24ea64fb8e43228d9f9669e2e4f03a
Autor:
Marie Deen, Edvige Correnti, Katharina Kamm, Tim Kelderman, Laura Papetti, Eloisa Rubio-Beltrán, Simone Vigneri, Lars Edvinsson, Antoinette Maassen Van Den Brink, On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
Publikováno v:
The Journal of Headache and Pain, Vol 18, Iss 1, Pp 1-9 (2017)
Abstract Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, dep
Externí odkaz:
https://doaj.org/article/d2ba45670bee4a83b7dd02bf83f5592e
Autor:
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, Victoria Ruschil, Till Sprenger, David Lewis, Katharina Kamm, Tobias Freilinger, Lars Neeb, Volker Malzacher, Uwe Meier, Klaus Gehring, Torsten Kraya, Thomas Dresler, Christoph J. Schankin, Andreas R. Gantenbein, Gregor Brössner, Karin Zebenholzer, Hans-Christoph Diener, Charly Gaul, Tim P. Jürgens
Publikováno v:
Der Nervenarzt. 94:306-317
ZusammenfassungMigräne ist die häufigste neurologische Erkrankung und kann mit einem hohen Grad der Beeinträchtigung einhergehen. Neben nichtmedikamentösen Ansätzen zur Reduktion der Migränefrequenz stehen medikamentöse Migräneprophylaxen zur
Autor:
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, Victoria Ruschil, Till Sprenger, David Lewis, Katharina Kamm, Tobias Freilinger, Lars Neeb, Volker Malzacher, Uwe Meier, Klaus Gehring, Torsten Kraya, Thomas Dresler, Christoph J. Schankin, Andreas R. Gantenbein, Gregor Brössner, Karin Zebenholzer, Hans-Christoph Diener, Charly Gaul, Tim P. Jürgens
Publikováno v:
Nervenarzt
In diesem Artikel waren die Adressdaten für den Autor Lars Neeb falsch angegeben. Statt „Neurologische Klinik und Poliklinik, Institut für Public Health, Charité – Universitätsmedizin Berlin, Freie Universität Berlin und Humboldt Universitä
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4def245a914fd0418c7f0afa03b476
https://www.ncbi.nlm.nih.gov/pubmed/36662297
https://www.ncbi.nlm.nih.gov/pubmed/36662297
Publikováno v:
Nervenheilkunde. 40:1017-1020
Autor:
Andreas Peikert, Katharina Kamm, Lucas Hendrik Overeem, Maxi Dana Hofacker, Lars Neeb, Astrid Gendolla, Bianca Raffaelli, Ruth Ruscheweyh, Uwe Reuter
Publikováno v:
Cephalalgia. 42:291-301
Background Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody (mAb), but there are no efficacy data so far. In this real-world analysis, we